Click HERE to access the handout
If you are a speech-language pathologist and would like a certificate for viewing this on demand webinar, please follow the below steps:
- View the webinar in its entirety.
- Click HERE to complete survey
- LSVT Global will verify your viewing of the webinar and email you a certificate.
NOTE: This LSVT Global webinar is not state or ASHA-registered for CEUs so you will need to retain your certificate if you would like to self-report your activity.
Join us for an informative webinar exploring the evolution and impact of LSVT LOUD, an evidence-based speech treatment approach for individuals with Parkinson’s disease and other neurological conditions. LSVT LOUD is a specialized voice therapy program designed to improve vocal loudness and overall communication abilities.
In this webinar, we will delve into the fascinating history of LSVT LOUD, tracing its origins, development, and transformative impact on individuals living with Parkinson’s disease. We will explore the underlying principles and techniques employed in LSVT LOUD, shedding light on the science behind this efficacious therapy.
Additionally, our expert presenters will discuss the application of LSVT LOUD to individuals with other neurological conditions, including pediatric populations. The presentation will provide valuable insights into the latest advancements and research findings related to LSVT LOUD, highlighting its continued effectiveness in the present day. The webinar will include success stories, research, and clinical outcomes achieved by LSVT LOUD over the years, showcasing the positive impact it has had on individuals worldwide.
Whether you are a speech-language pathologist, healthcare professional, researcher, or someone interested in learning more about voice and speech therapy, this webinar offers a unique opportunity to gain valuable insights into the past and present of LSVT LOUD. Discover how this innovative therapy approach has revolutionized the field of speech therapy and improved the lives of individuals with Parkinson’s disease and other neurological conditions.